SCHEMBL10168943

SCHEMBL10168943

Clc1nc(NC2CC2)nc(NC2CC2)n1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.66
RAB9A P51151 1/20 0.51
CYP2C9 P11712 1/20 0.49
NPR3 P17342 1/20 0.49
CYP2C19 P33261 1/20 0.49
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK1 P28482 2/20 0.38
IDH1 O75874 3/20 0.38
IDH2 P48735 2/20 0.38
PTGS2 P35354 1/20 0.37
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127390 0.95 PDE4A (0.60) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL1412368 0.89 PDE4A (0.56) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL11474250 0.89 PDE4A (0.83) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL10156650 0.89 PDE4A (0.66) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL18557112 0.89 PDE4A (0.82) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL18760598 0.89 PDE4A (0.82) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL18557113 0.89 PDE4A (0.82) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL11794474 0.89 PDE4A (0.82) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL20402878 0.89 PDE4A (0.82) PDE4ARAB9ACYP2C9NPR3CYP2C19
SCHEMBL20402877 0.89 PDE4A (0.82) PDE4ARAB9ACYP2C9NPR3CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160256463-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS INC (US) 2016-09-08 US disclosed
US-20160256463-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS INC (US) 2016-09-08 US disclosed
US-9351972-B2 Compounds as respiratory stimulants for treatment of breathing control disorders or diseases GALLEON PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351972-B2 Compounds as respiratory stimulants for treatment of breathing control disorders or diseases GALLEON PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
EP-2417129-B1 TRIAZINE-ARYL-BIS-INDOLES AS PDE-4 INHIBITORS USEFUL FOR THE TREATMENT OF ASTHMA COUNCIL SCIENT IND RES (IN) 2016-03-23 EP disclosed
US-20150374706-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. 2015-12-31 US disclosed
US-20150374706-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. 2015-12-31 US disclosed
US-9162992-B2 Compounds and compositions for treatment of breathing control disorders or diseases GALLEON PHARMACEUTICALS, INC. (US) 2015-10-20 US disclosed
US-9162992-B2 Compounds and compositions for treatment of breathing control disorders or diseases GALLEON PHARMACEUTICALS, INC. (US) 2015-10-20 US disclosed
US-9085559-B2 Triazine-aryl-bis-indoles and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-07-21 US disclosed
US-20140371224-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. 2014-12-18 US disclosed
US-20140371224-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. 2014-12-18 US disclosed
WO-2013181217-A2 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. (US) 2013-12-05 WO disclosed
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-11-22 US disclosed
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-11-22 US disclosed
US-20120283263-A1 TRIAZINE-ARYL-BIS-INDOLES AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-11-08 US disclosed
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-06-07 US disclosed
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-06-07 US disclosed
US-4187305-A 2,4-DIAMINO-6-CYCLOPROPYL-5-TRIAZINE CIBA-GEIGY CORPORATION (US) 1980-02-05 US disclosed
US-4187304-A 2,4-DIAMINO-6-CYCLOPROPYLAMINE-5-TRIAZINE CIBA-GEIGY CORPORATION (US) 1980-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases MTNR1B, CHRM3, ADRA2C PDE4A 6/4885RAB9A 2226/4885CYP2C9 2088/4885
US-20120283263-A1 TRIAZINE-ARYL-BIS-INDOLES AND PROCESS FOR PREPARATION THEREOF AHR, IDO2, IDO1 PDE4A 636/4885RAB9A 3417/4885CYP2C9 255/4885
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases PER2, SMPD4, NDUFB5 PDE4A 41/4885RAB9A 2307/4885CYP2C9 3237/4885
US-20140371224-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES PER2, MTNR1B, NDUFB5 PDE4A 94/4885RAB9A 2219/4885CYP2C9 4399/4885
US-20160256463-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES P2RX5, HRH2, ADRA2C PDE4A 9/4885RAB9A 3393/4885CYP2C9 2459/4885
US-20150374706-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES PER2, SMPD4, NDUFB5 PDE4A 41/4885RAB9A 2307/4885CYP2C9 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.